VXRT — Vaxart, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 72444 ·
Last close
$0.45
Market Cap
$109.43M
52W High
$0.84
52W Low
$0.31
ADV30
281,517
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 27,185,000 | — | -13,172,000 | -13,494,000 | 165,185,000 | 50,929,000 | 82,814,000 |
| Mar 2026 | 39,227,000 | — | 5,173,000 | 5,179,000 | 180,055,000 | 50,746,000 | 85,938,000 |
| Dec 2025 | 104,239,000 | — | 55,423,000 | 55,045,000 | 186,079,000 | 53,814,000 | 98,281,000 |
| Sep 2025 | 72,413,000 | — | -7,811,000 | -8,141,000 | 208,988,000 | 16,880,000 | 182,232,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,259,000
Investing CF
$2,724,000
Financing CF
$4,065,000
CapEx
$-696,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.16
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-455,016,000
Inventory
—
Receivables
$57,574,000
ST Investments
$10,276,000
EBIT TTM
$39,838,000
Pretax Income TTM
$37,507,000
Interest Exp TTM
$2,331,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$243,064,992
EBITDA
$45,616,000
Free Cash Flow
$-17,148,376
Enterprise Value
$66,337,148
Total Cash
$63,976,000
Total Debt
$12,538,000
Shares Out
243,186,939
Trailing EPS
$0.17
Book Value
$0.39
ROE
67.0%
ROA
15.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 237,258,000 | 18,074,000 | 16,327,000 | 186,079,000 | 98,281,000 | 87,798,000 | 7,714,000 |
| Dec 2024 | 28,700,000 | -66,293,000 | -66,948,000 | 166,389,000 | 107,464,000 | 58,925,000 | -44,764,000 |
| Dec 2023 | 7,379,000 | -83,347,000 | -82,465,000 | 91,830,000 | 34,025,000 | 57,805,000 | -70,453,000 |
| Dec 2022 | 107,000 | -110,333,000 | -107,758,000 | 153,847,000 | 43,250,000 | 110,597,000 | -94,779,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | $107.73M | $1.88 | — |
| CLLS | Cellectis S.A. | $106.90M | $1.47 | — |
| LENZ | LENZ Therapeutics, Inc. | $123.01M | $3.91 | — |
| CRDF | Cardiff Oncology, Inc. | $96.47M | $1.24 | — |
| NMRA | Neumora Therapeutics, Inc. | $127.39M | $0.68 | — |
News headlines (Yahoo Finance, 1h cache)
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
2026-09-15 06:02 · Yahoo
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
2026-08-26 20:07 · Yahoo
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
2026-08-11 01:07 · Yahoo
Vaxart Q2 Earnings Call Highlights
2026-08-09 20:03 · Yahoo
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
2026-07-30 12:00 · Yahoo
Vaxart to Participate in BTIG Biotechnology Conference 2026
2026-07-21 12:00 · Yahoo
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
2026-07-20 10:02 · Yahoo
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
2026-07-01 20:00 · Yahoo
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
2026-06-26 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.